BR9609666A - Composição farmacêutica de amiodarona para administração parenteral - Google Patents

Composição farmacêutica de amiodarona para administração parenteral

Info

Publication number
BR9609666A
BR9609666A BR9609666A BR9609666A BR9609666A BR 9609666 A BR9609666 A BR 9609666A BR 9609666 A BR9609666 A BR 9609666A BR 9609666 A BR9609666 A BR 9609666A BR 9609666 A BR9609666 A BR 9609666A
Authority
BR
Brazil
Prior art keywords
pct
amiodarone
pharmaceutical composition
parenteral administration
sec
Prior art date
Application number
BR9609666A
Other languages
English (en)
Inventor
Jean-Claude Gautier
Regine Bellamy
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR9609666A publication Critical patent/BR9609666A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9609666A 1995-06-30 1996-06-28 Composição farmacêutica de amiodarona para administração parenteral BR9609666A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9507939A FR2735978B1 (fr) 1995-06-30 1995-06-30 Composition pharmaceutique d'amiodarone pour administration parenterale
PCT/FR1996/001010 WO1997002031A1 (fr) 1995-06-30 1996-06-28 Composition pharmaceutique d'amiodarone pour administration parenterale

Publications (1)

Publication Number Publication Date
BR9609666A true BR9609666A (pt) 1999-05-25

Family

ID=9480596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609666A BR9609666A (pt) 1995-06-30 1996-06-28 Composição farmacêutica de amiodarona para administração parenteral

Country Status (14)

Country Link
US (1) US6143778A (pt)
EP (1) EP0835105B1 (pt)
JP (1) JP3137987B2 (pt)
AT (1) ATE213940T1 (pt)
AU (1) AU6462596A (pt)
BR (1) BR9609666A (pt)
CA (1) CA2222304C (pt)
DE (1) DE69619673T2 (pt)
ES (1) ES2174083T3 (pt)
FR (1) FR2735978B1 (pt)
MX (1) MX9710206A (pt)
NO (1) NO317061B1 (pt)
WO (1) WO1997002031A1 (pt)
ZA (1) ZA965525B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861539B1 (en) 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US7339078B2 (en) * 1995-03-10 2008-03-04 G.D. Searle Llc Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
US6646195B1 (en) * 2000-04-12 2003-11-11 Microsoft Corporation Kernel-mode audio processing modules
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20020143051A1 (en) 2001-03-29 2002-10-03 Doty Mark J. Premixed amiodarone parenteral solution and method for making the same
MXPA03008857A (es) * 2001-03-29 2004-05-24 Baxter Int Solucion parenteral de amiodarona premezclada y metodo para elaboracion de la misma.
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
JP2004535432A (ja) * 2001-06-22 2004-11-25 ベントレー ファーマシューティカルズ インコーポレイテッド 医薬組成物
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
PT2279729T (pt) * 2003-07-17 2016-09-22 Banner Life Sciences Llc Preparações de libertação controlada
EP1661556A4 (en) * 2003-08-20 2010-05-19 Ajinomoto Kk MEDICAL PREPARATION WITH IMPROVED RESOLUTION CHARACTERISTICS
KR100926915B1 (ko) 2004-04-26 2009-11-17 미쓰비시 마테리알 가부시키가이샤 폐수 처리방법 및 폐수 처리장치
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
JP5584486B2 (ja) * 2009-02-16 2014-09-03 株式会社クラレ バラスト水製造装置
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
US20120142768A1 (en) 2010-06-11 2012-06-07 Baxter Healthcare S.A. Formulations including amiodarone and salts thereof and methods of their manufacture and use
JP6913458B2 (ja) * 2014-05-28 2021-08-04 武田薬品工業株式会社 抗菌水
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
US20220016070A1 (en) * 2020-07-17 2022-01-20 Good Health, Llc Premixed, ready to use pharmaceutical compositions of amiodarone
CN112472668B (zh) * 2020-10-29 2023-02-28 太阳升(亳州)生物医药科技有限公司 用于制备盐酸胺碘酮注射液的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234949A (en) * 1992-04-01 1993-08-10 Academic Pharmaceuticals, Inc. Parenteral solutions containing amiodarone in acetate buffer solution

Also Published As

Publication number Publication date
ATE213940T1 (de) 2002-03-15
NO976125D0 (no) 1997-12-29
US6143778A (en) 2000-11-07
CA2222304C (fr) 2002-09-17
NO976125L (no) 1998-02-26
ZA965525B (en) 1997-12-29
MX9710206A (es) 1998-03-31
ES2174083T3 (es) 2002-11-01
NO317061B1 (no) 2004-08-02
WO1997002031A1 (fr) 1997-01-23
DE69619673D1 (de) 2002-04-11
CA2222304A1 (fr) 1997-01-23
JP3137987B2 (ja) 2001-02-26
FR2735978A1 (fr) 1997-01-03
FR2735978B1 (fr) 1997-09-19
AU6462596A (en) 1997-02-05
JPH10510297A (ja) 1998-10-06
DE69619673T2 (de) 2002-11-14
EP0835105A1 (fr) 1998-04-15
EP0835105B1 (fr) 2002-03-06

Similar Documents

Publication Publication Date Title
ES2174083T3 (es) Composicion farmaceutica de amiodarona para administracion parenteral.
ES2145158T3 (es) Nueva formulacion de emulsion.
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
BR9509975A (pt) Formulação farmacêutica
CA2203310A1 (fr) Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
SI0833640T1 (en) Pharmaceutical composition containing lamotrigine
NZ234451A (en) Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions

Legal Events

Date Code Title Description
TE Change of address
PC Transfer

Free format text: SANOFI SYNTHELABO (FR)

FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FF Decision: intention to grant
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
HIFF Patent grant cancelled
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2261 DE 06-05-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.